Provided by Tiger Trade Technology Pte. Ltd.

Fulcrum Therapeutics

7.65
+0.02000.26%
Post-market: 7.650.00000.00%16:10 EDT
Volume:536.83K
Turnover:4.05M
Market Cap:509.49M
PE:-6.47
High:7.83
Open:7.63
Low:7.34
Close:7.63
52wk High:15.74
52wk Low:2.32
Shares:66.60M
Float Shares:39.39M
Volume Ratio:0.56
T/O Rate:1.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1819
EPS(LYR):-1.1819
ROE:-25.30%
ROA:-16.90%
PB:1.46
PE(LYR):-6.47

Loading ...

Chief Legal Officer Curt Oltmans Reports Sale of Fulcrum Therapeutics Common Shares

Reuters
·
Dec 18, 2025

Fulcrum Therapeutics Is Maintained at Buy by Truist Securities

Dow Jones
·
Dec 12, 2025

RA Capital Management Reports Sale of Fulcrum Therapeutics Common Shares

Reuters
·
Dec 11, 2025

BRIEF-Fulcrum Therapeutics Announces Pricing Of Upsized $175.0 Million Public Offering Of Common Stock And Pre-Funded Warrants

Reuters
·
Dec 10, 2025

Fulcrum Therapeutics Inc - Prices Public Offering of 11.85 Mln Shares at $13.50

THOMSON REUTERS
·
Dec 10, 2025

Fulcrum Therapeutics Is Maintained at Underperform by B of A Securities

Dow Jones
·
Dec 10, 2025

BUZZ-Fulcrum Therapeutics dips after unveiling $150 million share sale

Reuters
·
Dec 09, 2025

Press Release: Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock

Dow Jones
·
Dec 09, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Five Below, Boeing, Instacart

Reuters
·
Dec 09, 2025

Fulcrum Therapeutics Up Nearly 59%, on Pace for Largest Percent Increase Since August 2021 -- Data Talk

Dow Jones
·
Dec 09, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Micron, NextEra Energy, Ocular Therapeutix

Reuters
·
Dec 08, 2025

BUZZ-Fulcrum Therapeutics rises after trial data of blood disorder drug

Reuters
·
Dec 08, 2025

Fulcrum Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 08, 2025

Fulcrum Therapeutics Shares up 49.1% Premarket After Positive Early-Stage Trial Data of Blood Disorder Drug

THOMSON REUTERS
·
Dec 08, 2025

RBC Raises Price Target on Fulcrum Therapeutics to $10 From $7, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
Dec 08, 2025

Fulcrum Therapeutics Inc : Leerink Partners Raises Target Price to $24 From $20

THOMSON REUTERS
·
Dec 08, 2025

Fulcrum Shares Soar on Sickle-Cell Treatment Trial Results

Dow Jones
·
Dec 08, 2025

Fulcrum Therapeutics Reports Positive Initial Results from Trial of Pociredir in Sickle Cell Disease; Shares Surge Pre-Bell

MT Newswires Live
·
Dec 08, 2025

Fulcrum Therapeutics Reports Positive Phase 1b Results for Pociredir in Sickle Cell Disease

Reuters
·
Dec 07, 2025

Fulcrum Therapeutics Announces Positive Initial Results From the 20 Mg Dose Cohort of the Phase 1B Pioneer Trial of Pociredir in Sickle Cell Disease at the 67TH American Society of Hematology Annual Meeting

THOMSON REUTERS
·
Dec 07, 2025